Oxycodone/Naloxone, Oral: References

TARGINIQ ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), for oral use, CII. PURDUE PHARMA LP. Drugs@FDA. US Food and Drug Administration. Accessed August 18, 2016 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205777lbl.pdf

US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Accessed August 19, 2016 from http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm. Published March 22, 2016.

Personal Communication on August 18, 2016. Medical Services. Purdue Pharma LP. Phone: 888‑726‑7535. Re: Targiniq ER has not been launched (since FDA approval July 2014), per a marketing decision. Launch is on hold; anticipated availability is currently unknown.

Oxycodone and Naloxone. Lexi-Comp ONLINE, 2016 Lexi-Comp, Inc. Accessed August 18, 2016 from http://online.lexi.com.

Oxycodone/Naloxone. DRUGDEX® System. 2016 Truven Health Analytics Inc. Accessed August 18, 2016 from http://www.thomsonhc.com